Header Logo

Connection

JOSEPH JANKOVIC to Botulinum Toxins

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Botulinum Toxins.
JOSEPH JANKOVIC
Connection Strength
13.835
Botulinum Toxins
  1. Botulinum Toxin for the Treatment of Tremors. Toxins (Basel). 2025 Aug 11; 17(8).
    View in: PubMed
    Score: 0.842
  2. Botulinum toxin treatment in parkinsonism. J Neurol Sci. 2024 01 15; 456:122810.
    View in: PubMed
    Score: 0.748
  3. Botulinum Neurotoxin Injections in Children with Self-Injurious Behaviors. Toxins (Basel). 2023 03 23; 15(4).
    View in: PubMed
    Score: 0.713
  4. Exploring the role of botulinum toxin in critical care. Expert Rev Neurother. 2021 08; 21(8):881-894.
    View in: PubMed
    Score: 0.638
  5. Botulinum Neurotoxin Injections in Childhood Opisthotonus. Toxins (Basel). 2021 02 12; 13(2).
    View in: PubMed
    Score: 0.617
  6. Botulinum Toxin in Movement Disorders: An Update. Toxins (Basel). 2021 Jan 08; 13(1).
    View in: PubMed
    Score: 0.612
  7. Botulinum toxin for the treatment of tremor. Parkinsonism Relat Disord. 2019 06; 63:31-41.
    View in: PubMed
    Score: 0.535
  8. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon. 2018 Jun 01; 147:84-88.
    View in: PubMed
    Score: 0.486
  9. Botulinum toxin: State of the art. Mov Disord. 2017 Aug; 32(8):1131-1138.
    View in: PubMed
    Score: 0.479
  10. Botulinum Toxin for the Treatment of Tremor and Tics. Semin Neurol. 2016 Feb; 36(1):54-63.
    View in: PubMed
    Score: 0.436
  11. Therapeutic Developments for Tics and Myoclonus. Mov Disord. 2015 Sep 15; 30(11):1566-73.
    View in: PubMed
    Score: 0.422
  12. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon. 2014 Nov; 90:344-8.
    View in: PubMed
    Score: 0.393
  13. Flu-like symptoms and associated immunological response following therapy with botulinum toxins. Neurotox Res. 2013 Aug; 24(2):298-306.
    View in: PubMed
    Score: 0.360
  14. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel). 2013 Feb 04; 5(2):249-66.
    View in: PubMed
    Score: 0.354
  15. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol. 2009 Dec; 16 Suppl 2:14-8.
    View in: PubMed
    Score: 0.284
  16. Unique properties of botulinum toxins. Toxicon. 2009 Oct; 54(5):675.
    View in: PubMed
    Score: 0.267
  17. Disease-oriented approach to botulinum toxin use. Toxicon. 2009 Oct; 54(5):614-23.
    View in: PubMed
    Score: 0.265
  18. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm (Vienna). 2008; 115(4):585-91.
    View in: PubMed
    Score: 0.239
  19. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev Neurother. 2007 Jun; 7(6):637-47.
    View in: PubMed
    Score: 0.238
  20. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5.
    View in: PubMed
    Score: 0.231
  21. Botulinum toxin therapy for cervical dystonia. Neurotox Res. 2006 Apr; 9(2-3):145-8.
    View in: PubMed
    Score: 0.220
  22. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005 Sep 13; 65(5):765-7.
    View in: PubMed
    Score: 0.212
  23. Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J. 2005 Mar; 20(1):44-7.
    View in: PubMed
    Score: 0.204
  24. Treatment of cervical dystonia with botulinum toxin. Mov Disord. 2004 Mar; 19 Suppl 8:S109-15.
    View in: PubMed
    Score: 0.190
  25. Dystonia: medical therapy and botulinum toxin. Adv Neurol. 2004; 94:275-86.
    View in: PubMed
    Score: 0.188
  26. Botulinum toxin for the treatment of cervical dystonia. Expert Opin Pharmacother. 2001 Dec; 2(12):1985-94.
    View in: PubMed
    Score: 0.163
  27. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve. 2001 Nov; 24(11):1568-70.
    View in: PubMed
    Score: 0.162
  28. Focal dystonia: the role of botulinum toxin. Curr Neurol Neurosci Rep. 2001 Jul; 1(4):337-45.
    View in: PubMed
    Score: 0.158
  29. Botulinum toxin in the treatment of tics. Arch Neurol. 2000 Aug; 57(8):1190-3.
    View in: PubMed
    Score: 0.149
  30. Treatment of Tardive Dyskinesia. Neurol Clin. 2020 05; 38(2):379-396.
    View in: PubMed
    Score: 0.144
  31. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology. 1998 Jun; 50(6):1624-9.
    View in: PubMed
    Score: 0.128
  32. Toxins 2017 conference in Madrid. Toxicon. 2018 Jun 01; 147:1.
    View in: PubMed
    Score: 0.126
  33. Medical therapy and botulinum toxin in dystonia. Adv Neurol. 1998; 78:169-83.
    View in: PubMed
    Score: 0.124
  34. Apraclonidine in the treatment of ptosis. J Neurol Sci. 2017 May 15; 376:129-132.
    View in: PubMed
    Score: 0.118
  35. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl. 1997; 6:S129-45.
    View in: PubMed
    Score: 0.116
  36. Treatment of blepharospasm with apraclonidine. J Neurol Sci. 2017 Jan 15; 372:57-59.
    View in: PubMed
    Score: 0.115
  37. Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. Drugs. 2016 May; 76(7):779-87.
    View in: PubMed
    Score: 0.111
  38. Response and immunoresistance to botulinum toxin injections. Neurology. 1995 Sep; 45(9):1743-6.
    View in: PubMed
    Score: 0.106
  39. Botulinum toxin in movement disorders. Curr Opin Neurol. 1994 Aug; 7(4):358-66.
    View in: PubMed
    Score: 0.098
  40. Botulinum toxin in the treatment of dystonic tics. Mov Disord. 1994 May; 9(3):347-9.
    View in: PubMed
    Score: 0.096
  41. Treatment of dystonia. Neurotherapeutics. 2014 Jan; 11(1):139-52.
    View in: PubMed
    Score: 0.094
  42. Use of botulinum toxin in the treatment of hand dystonia. J Hand Surg Am. 1993 Sep; 18(5):883-7.
    View in: PubMed
    Score: 0.092
  43. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013 Nov; 28(13):1775-83.
    View in: PubMed
    Score: 0.091
  44. Medical treatment of dystonia. Mov Disord. 2013 Jun 15; 28(7):1001-12.
    View in: PubMed
    Score: 0.091
  45. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology. 1993 Apr; 43(4):834-6.
    View in: PubMed
    Score: 0.089
  46. Clinical correlates of response to botulinum toxin injections. Arch Neurol. 1991 Dec; 48(12):1253-6.
    View in: PubMed
    Score: 0.081
  47. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
    View in: PubMed
    Score: 0.081
  48. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology. 2012 Jan; 217(1):17-27.
    View in: PubMed
    Score: 0.080
  49. Flu-like symptoms following botulinum toxin therapy. Toxicon. 2011 Jul; 58(1):1-7.
    View in: PubMed
    Score: 0.078
  50. Therapeutic uses of botulinum toxin. N Engl J Med. 1991 Apr 25; 324(17):1186-94.
    View in: PubMed
    Score: 0.078
  51. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990 Aug; 53(8):633-9.
    View in: PubMed
    Score: 0.074
  52. Botulinum toxin injections for cervical dystonia. Neurology. 1990 Feb; 40(2):277-80.
    View in: PubMed
    Score: 0.072
  53. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008 Sep; 45(15):3878-88.
    View in: PubMed
    Score: 0.065
  54. Role of botulinum toxin in the treatment of cervical dystonia. Neurol Clin. 2008 May; 26 Suppl 1:43-53.
    View in: PubMed
    Score: 0.064
  55. Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy. Adv Neurol. 1988; 50:583-91.
    View in: PubMed
    Score: 0.062
  56. Botulinum A toxin in the treatment of blepharospasm. Adv Neurol. 1988; 49:467-72.
    View in: PubMed
    Score: 0.062
  57. Treatment of dystonia. Parkinsonism Relat Disord. 2007; 13 Suppl 3:S362-8.
    View in: PubMed
    Score: 0.058
  58. Runner's dystonia. J Neurol Sci. 2006 Dec 21; 251(1-2):73-6.
    View in: PubMed
    Score: 0.057
  59. Treatment of dystonia. Lancet Neurol. 2006 Oct; 5(10):864-72.
    View in: PubMed
    Score: 0.057
  60. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest. 2002 Aug-Nov; 31(3-4):247-62.
    View in: PubMed
    Score: 0.043
  61. Dystonia in corticobasal degeneration. Mov Disord. 2001 Mar; 16(2):252-7.
    View in: PubMed
    Score: 0.039
  62. Psychogenic hemifacial spasm. J Neuropsychiatry Clin Neurosci. 2001; 13(3):380-4.
    View in: PubMed
    Score: 0.038
  63. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry. 2000 Feb; 68(2):186-90.
    View in: PubMed
    Score: 0.036
  64. Bruxism and cranial-cervical dystonia: is there a relationship? Cranio. 1999 Jul; 17(3):196-201.
    View in: PubMed
    Score: 0.034
  65. Bilateral hemifacial spasm: a report of five cases and a literature review. Mov Disord. 1999 Mar; 14(2):345-9.
    View in: PubMed
    Score: 0.034
  66. Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry. 1998 Nov; 65(5):722-8.
    View in: PubMed
    Score: 0.033
  67. Severe motor tics causing cervical myelopathy in Tourette's syndrome. Mov Disord. 1996 Sep; 11(5):563-6.
    View in: PubMed
    Score: 0.028
  68. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord. 1996 Jul; 11(4):431-3.
    View in: PubMed
    Score: 0.028
  69. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord. 1998 Jan; 13(1):150-4.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.